Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Baxter
McKesson
Express Scripts
Medtronic
Boehringer Ingelheim

Last Updated: October 16, 2019

DrugPatentWatch Database Preview

Claims for Patent: 7,399,632

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,399,632
Title:Mesenchymal precursor cell
Abstract: A method of enriching mesenchymal precursor sells including the step of enriching for cells based on at least two markers. The markers may be either i) the presence of markers specific for mesenchymal precursor cells, ii) the absence of markers specific for differentiated mesenchymal cells, or iii) expression levels of markers specific for mesenchymal precursor cells. The method may include a first solid phase sorting step utilizing MACS recognizing expression of the antigen to the STRO-1 Mab, followed by a second sorting step utilizing two color FACS to screen for the presence of high level STRO-1 antigen expression as well as the expression of VCAM-1.
Inventor(s): Simmons; Paul (East Melbourne, AU), Zannettino; Andrew (Adelaide, AU), Gronthos; Stan (Bethesda, MD)
Assignee: Angioblast Systems, Incorporated (New York, NY)
Application Number:11/178,920
Patent Claims:1. A method of preparing a population of cells enriched for mesenchymal precursor cells, comprising treating the population of cells so as to enrich for cells which are STRO-1.sup.bright.

2. A method of claim 1, wherein the enrichment results in a cell population in which at least 1.5% of the cells are STRO-1.sup.bright.

3. A method of claim 2, wherein the enrichment results in a cell population in which at least 2% of the cells are STRO-1.sup.bright.

4. A method of claim 1, wherein the enrichment is for cells that also express at least one other antigen selected from the group consisting of LFA-3, ICAM-1, PECAM-1, P-selectin. L-selectin, CD49b/CD29, CD49c/CD29, CD49d/CD29, CD29, CD18, CD61, 6-19, thrombomodulin, telomerase, CD10, CD13, integrin beta, and SCF.

5. A method of claim 1, wherein the enrichment results in a cell population in which at least 1% of the cells are capable of giving rise to colony forming units-fibroblast (CFU-F).

6. A method of claim 1, wherein the enrichment results in a cell population in which at least 5% of the cells are capable of giving rise to colony forming units-fibroblast (CFU-F).

7. A method of claim 1, wherein the enrichment results in a cell population in which at least 10% of the cells are capable of giving rise to colony forming units-fibroblast (CFU-F).

8. A method of claim 1, wherein the enrichment results in a cell population in which at least 40% of the cells are capable of giving rise to colony forming units-fibroblast (CFU-F).

9. A method of claim 1, wherein the enrichment results in a cell population in which at least 2% of cells carry both the antigen identified by STRO-1 and VCAM-1.

10. A mechod of claim 1, wherein the STRO-1.sup.bright cells are negative for at lease one marker selected from the group consisting of CBFA-1, collagen type II, PPAR.gamma.2, osetopontin, ostelcalcin, parathyroid hormone receptor, leptin, H-ALBP, aggrecan, Ki67, and glycophorin A.

11. A method of claim 1, wherein at least a proportion of the enriched cells are capable of differentiation into at least two conmtitted cell types selected from the group comprising adipose, areolar. osseous, cartilaginous, elastic, and fibrous connective tissue.

12. A method of claim 1, further comprising transforming the cells with an exogenous nucleic acid.

13. A method of claim 1, wherein the source of the population of cells is stromal stem cells from one or more of bone marrow, blood, epidermis and hair follicles.

14. A method of claim 13, wherein the population of cells is from bone marrow.

15. A method of claim 1, further comprising harvesting the population of the cells from a source before treating to enrich.

16. The method of claim 1, wherein the enrichment is for cells that also express at least one other marker selected from VACM-1, TKY-1, CD146 and STRO-2.

17. The method of claim 1, wherein the mechod comprises a separation step based on recognition of cells carrying the STRO-1marker.

18. The method of claim 17, wherein recognition of the cell carrying the STRO-1 marker is achieved by a binding agent to the STRO-1 marker.

19. The method of claim 18, wherein the binding agent is a monoclonal antibody or molecule based on a monoclonal antibody.

Summary for Patent:   Start Trial

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
AustraliaPQ1477Jul 7, 1999

Details for Patent 7,399,632

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 001 2015-01-23   Start Trial Angioblast Systems, Incorporated (New York, NY) 2019-07-07 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 002 2015-01-23   Start Trial Angioblast Systems, Incorporated (New York, NY) 2019-07-07 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 003 2015-01-23   Start Trial Angioblast Systems, Incorporated (New York, NY) 2019-07-07 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 004 2015-01-23   Start Trial Angioblast Systems, Incorporated (New York, NY) 2019-07-07 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 7,399,632

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
McKesson
Johnson and Johnson
Mallinckrodt
Boehringer Ingelheim
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.